Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of CT-868 in Type 1 Diabetes Mellitus
Sponsor: Carmot Therapeutics, Inc.
Summary
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.
Official title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
111
Start Date
2023-11-27
Completion Date
2025-07-07
Last Updated
2026-10-28
Healthy Volunteers
No
Conditions
Interventions
CT-868
CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
CT-868 Pen Injector
The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
CT-868 Pen Injector, Placebo
The placebo pen injector is identical and contains the same ingredients except for CT-868.
Locations (22)
John Muir Physician Network Clinical Research Center
Concord, California, United States
Headlands Research- AMCR
Escondido, California, United States
University of Colorado - Barbara Davis Center for Diabetes
Aurora, Colorado, United States
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado, United States
Advent Health
Orlando, Florida, United States
Orlando Health Science Clinic, LLC
Orlando, Florida, United States
Innovative Research Institute
Port Charlotte, Florida, United States
Atlanta Diabetes Associates
Atlanta, Georgia, United States
Rocky Mountain Clinical Research, LLC- Idaho Falls, Idaho
Idaho Falls, Idaho, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
MedStar Health Research Institute - Washington Hospital Center
Hyattsville, Maryland, United States
University of North Carolina Health Sciences at MAHEC
Asheville, North Carolina, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Lucas Research, Inc
Morehead City, North Carolina, United States
Oregon Health and Science University
Portland, Oregon, United States
Texas Diabetes and Endocrinology, P.A
Austin, Texas, United States
Velocity Clinical Research - Dallas
Dallas, Texas, United States
Research Institute of Dallas
Dallas, Texas, United States
Diabetes & Glandular Disease Clinic, P.A.
San Antonio, Texas, United States
Consano Clinical Research
Shavano Park, Texas, United States
Texas Valley Clinical Research, LLC
Weslaco, Texas, United States
Rainier Clinical Research Center
Renton, Washington, United States